In clinical settings, understanding MuRF-1’s molecular responses can guide the development of personalized strategies for preventing muscular atrophy in older adults, reducing the impact of sarcopenia, preserving functional capacity, and improving quality of life. Here, TRIM63 is linked to sarcopenia.